Melanotan: Identity, Risks and Regulatory Warnings

What the name covers

Melanotan I and melanotan II are synthetic analogues (look-alikes) of alpha-melanocyte-stimulating hormone, or alpha-MSH, the natural signal that acts on skin pigment cells. [3] They are different molecules.

• Melanotan I is the name given to [Nle4-D-Phe7]-alpha-MSH in an early human study. [4] A medicine called afamelanotide is described with the same chemical name. [5]
• Melanotan II is a cyclic (ring-shaped) analogue. [6] It is a non-selective melanocortin receptor agonist, meaning it switches on several related receptors, and it can also cause spontaneous erections. [7]
• Bremelanotide is described as a variation of melanotan II designed for sexual stimulation. [8] It has its own page: Bremelanotide (PT-141).

So a brand, a molecule and a formulation are not interchangeable. A product sold as "melanotan" may not match any of them (see below).

An approved relative, and why it does not make the street product approved

In the European Union, Scenesse (active substance afamelanotide) is an implant authorised for adults with erythropoietic protoporphyria (EPP), a rare condition that causes intolerance to light. It is prescribed only by specialist doctors in recognised centres, and was authorised under "exceptional circumstances" because complete information was hard to obtain for such a rare disease. [9] That is a specific product, for a specific disease, with specialist supervision. It is not a tanning approval, and it says nothing about products bought online. A 2017 review made the same distinction: afamelanotide is the only alpha-MSH analogue approved, and only for limited medical uses. [3]

Regulatory position (read 2026-10-22; laws change, and this is not legal advice)

Compounding is not approval: the FDA page concerns what may be made by compounders, and says nothing that turns the substance into an approved drug.

What research shows

• Early human work (melanotan I). In a 1997 study of three male volunteers, injections under the skin darkened the forehead, arms and neck, with mostly mild stomach upset and flushing. [4] Three people is far too few to judge safety.
• Melanotan II. We found no controlled efficacy trial of melanotan II for tanning. Insufficient evidence of benefit and safety. A trial record on ClinicalTrials.gov for melanotan II in vitiligo (NCT07437560) is listed as recruiting, but its own text calls it an "example" record; do not treat it as established research. [11]
• Product reality. Studies of what people actually use are mostly surveys and online-forum analyses, which cannot show safety. [12][13]

Reported harms

These are case reports and reviews. They show that harms have been seen, not how common they are.

• Moles and melanoma. A review found four case reports of melanoma arising in existing moles during or soon after use, plus changes in moles and new atypical moles, and said conclusive evidence of cause was lacking. [3] One report describes a 20-year-old woman with melanoma after a short course combined with sunbed use. [6] Another describes melanoma in situ. [14]
• Muscle, kidney and circulation problems. Case reports describe muscle breakdown with kidney injury, a kidney infarction, and a prolonged painful erection (priapism). [8][7][15]
• Infection. Online discussions mention needle practices that risk blood-borne infection, contaminated product and sunbed use alongside. [13] A 2010 review notes the UK regulator's concern about needle sharing and impurity. [16]

Quality and labeling

Content and strength are unreliable. Laboratory testing of melanotan II vials bought from three online shops found 4.32 to 8.84 mg per vial where each shop claimed 10 mg, with unknown impurities in two. [17] The TGA tested seized nasal sprays labelled 30 mg and estimated 22 to 54 mg per bottle, and warned the variation raises the chance of adverse events. [1] Online products may also be fake or contain undisclosed ingredients. [1] Naming problems like these are covered in Research Peptide Naming and Identity Problems.

Who is most at risk

We did not find sourced guidance for pregnancy, children or other groups. People with many moles, a personal or family history of melanoma, or a new or changing spot should see a doctor or dermatologist and say if they have used these products. Sunbeds and sun add their own skin cancer risk. [2]

Safer questions to ask

If the goal is a tanned look, ask a pharmacist or dermatologist about sunless options, and see Skin Aging and Appearance. If you have used melanotan and have symptoms, or a mole that has changed, speak with a clinician. The TGA also advises people to stop using these products and report side effects. [1]